Drug Trial Radar · NCT05331690
Cataract Surgery and Inflammation - the Role for Preoperative NSAIDs (Pre-CIN)
Last checked: Nov 20, 2026Latest source record: Dec 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Nov 25, 2022
Primary completion
Aug 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Oslo University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The pre-CIN trial is a randomized clinical three-arm trial comparing inflammation and cystoid macular edema for the medication regimens preoperative and postoperative topical NSAIDs to only postoperative topical NSAIDs to postoperative topical NSAIDs and steroids in patients undergoing cataract surgery.
Conditions
- Cataract Surgery
Interventions
Nepafenac OphthalmicDrug
Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
Nepafenac OphthalmicDrug
Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
Dexamethasone OphthalmicDrug
Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Central macular thickness after 6 weeksTime frame: 6 weeks after surgery
- Cystoid macular edema (CME) after 6 weeksTime frame: 6 weeks after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Ophthalmology, Oslo University Hospital
Oslo, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.